Long-term desmopressin response in primary nocturnal enuresis: open-label, multinational study

Area of Science:

• Pediatric Nephrology
• Urology
• Pharmacology

Background:

• Primary nocturnal enuresis (PNE) significantly impacts quality of life, especially in severe cases.
• A common cause of PNE is insufficient nighttime release of antidiuretic hormone.
• Desmopressin, an antidiuretic hormone analogue, has shown promise in reducing wet nights.

Purpose of the Study:

• To evaluate the real-world efficacy and safety of desmopressin for severe PNE over 6 months.
• To identify predictive factors for desmopressin treatment response in children aged 5 and above.
• To assess long-term outcomes in a large, multi-country cohort.

Main Methods:

• A 6-month, real-world clinical study involving 744 children with severe PNE.
• Data collection on wet nights, treatment adherence, and adverse events.
• Logistic regression analysis to identify predictors of treatment response.

Main Results:

• 41% of patients achieved at least a 50% reduction in wet nights after 6 months.
• Treatment was well-tolerated, with only 5% experiencing adverse events.
• Nocturnal diuresis and patient age were significant predictors of response.

Conclusions:

• Long-term desmopressin treatment is effective and safe for children aged 5+ with PNE in a clinical setting.
• Early treatment response can enhance compliance and lead to better long-term outcomes.
• Persistent treatment is valuable for achieving significant reduction in wet nights.